Core Viewpoint - The company, Ascentage Pharma-B (06855), has seen a nearly 4% increase in stock price following the announcement of FDA approval for its new drug application for APG-3288, a next-generation BTK-targeted protein degrader aimed at treating relapsed/refractory B-cell malignancies [1] Group 1: Company Developments - Ascentage Pharma announced that its innovative drug APG-3288 has received IND approval from the FDA, allowing it to proceed with clinical research [1] - The clinical study will be a global, multi-center, open-label Phase I trial focused on evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies [1] Group 2: Market Reaction - Following the announcement, Ascentage Pharma's stock price rose by 3.69%, reaching HKD 53.4, with a trading volume of HKD 61.64 million [1]
亚盛医药-B涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可